BioSante to raise $25M in RDO; Archimedes to hire 75 new workers;

@FierceBiotech: FierceBiotech's Clinical Trials Executive Breakfast series heads to San Francisco. Article | Follow@FierceBiotech

@JohnCFierce: Here's the PR on tofacitinib, which is probably the best late-stage prospect Pfizer has now. I don't get name change. Item | Follow @JohnCFierce

> BioSante Pharmaceuticals will raise $25.1 million via a registered direct offering. The company is selling 12.2 million shares with the possibility of selling another 4 million shares. BioSante will use the investment to continue its Phase III trials of LibiGel, a transdermal testosterone gel for female sexual dysfunction. BioSante release

> Cambridge, UK-based Sareum Holdings has released preclinical trial results showing that its cancer growth inhibitor lowered cancer growth rates at a greater rate than chemotherapy alone. Article

> Archimedes Pharma will hire 75 new workers in the next two years for its Bedminster, NJ offices, partly thanks to a grant worth $2.1 million over 10 years from the New Jersey Economic Development Authority. Item

And Finally... According to a NIAID-sponsored study, raltegravir chewable tablets can keep HIV controlled in children ages two to five, with 71 percent of participants having a 90 percent reduction in their HIV copies circulating after 24 weeks of treatment. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.